CAPTRUST Financial Advisors
CPRX

CAPTRUST Financial Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$773K Sell
24,580
-11,610
-32% -$343K ﹤0.01% 1881
2026
Q1 		$896K Buy
36,190
+1,630
+5% +$38.8K ﹤0.01% 1677
2025
Q4 		$807K Buy
34,560
+14,926
+76% +$332K ﹤0.01% 1622
2025
Q3 		$387K Sell
19,634
-2,114
-10% -$43.5K ﹤0.01% 1996
2025
Q2 		$472K Buy
+21,748
New +$513K ﹤0.01% 1766
2022
Q3 		– Sell
-599
Closed -$4K – 2461
2022
Q2 		$4K Buy
599
+304
+103% +$2.23K ﹤0.01% 4169
2022
Q1 		$2K Sell
295
-1,170
-80% -$8.27K ﹤0.01% 4467
2021
Q4 		$10K Sell
1,465
-651
-31% -$4.28K ﹤0.01% 3700
2021
Q3 		$11K Sell
2,116
-113
-5% -$618 ﹤0.01% 3537
2021
Q2 		$13K Buy
2,229
+113
+5% +$583 ﹤0.01% 3372
2021
Q1 		$10K Buy
2,116
+1,989
+1,566% +$7.9K ﹤0.01% 3422
2020
Q4 		$0 Hold
127
– – ﹤0.01% 3416
2020
Q3 		$0 Buy
+127
New +$497 ﹤0.01% 3077

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CAPTRUST Financial Advisors's CPRX Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 32% in Q2 2026, selling an estimated $343K and leaving 24,580 shares worth $773K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

CAPTRUST Financial Advisors first reported a position in CPRX in Q3 2020 and has held it in 13 quarters since. The position peaked at $896K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • CAPTRUST Financial Advisors held 24,580 shares of Catalyst Pharmaceutical worth $773K as of Q2 2026.
  • CAPTRUST Financial Advisors sold 11,610 Catalyst Pharmaceutical shares in Q2 2026, an estimated $343K.
  • Catalyst Pharmaceutical made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1881 holding.
  • CAPTRUST Financial Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 13 quarters since.
  • CAPTRUST Financial Advisors's Catalyst Pharmaceutical position peaked at $896K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.